Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 16, 1992, Pages 2215-2220

  Carter, H Ballentine ^a   Pearson, Jay D ^a   Metter, E Jeffrey ^a   Brant, Larry J ^a   Fozard, James L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; GERONTOLOGICAL RESEARCH; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMAN; LONGITUDINAL STUDIES; LUTEINIZING HORMONE; MALE; MIDDLE AGE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; REGRESSION ANALYSIS; SUPPORT, U.S. GOV'T, P.H.S.; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0026522840     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03480160073037     Document Type: Article

References (19)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol. 1979;17:159-163.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
3. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate-specific antigen. J Urol. 1990;143:1146-1154.
4. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324:1156-1161.
5. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol. 1989;142:1011-1017.
6. Oesterling JE, Chan DW, Epstein JI, et al. Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766-772.
7. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostatespecific antigen levels in men with benign prostatic hyperplasia. J Urol. 1989;141:987-992.
8. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, IV: antiandrogen treated patients. J Urol. 1989;141:1088-1090.
9. Shock NW, Greulich RC, Andres R, et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: National Institutes of Health; 1984. National Institutes of Health publication 84-2450.
10. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 1990;16:253-261.
11. National Institutes of Health. 1987 Annual Annual Cancer Statistics Review. Washington, DC: National Institutes of Health; 1988. National Institutes of Health publication 88-2789.
12. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-246.
13. Lindstrom MJ, Bates DM. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc. 1988;83:1014-1022.
14. Pearson JD, Kaminski P, Morrell CH, et al. Modeling longitudinal rates of change in prostate-specific antigen during aging. In: Proceedings of the American Statistical Association Meetings: Social Statistics Section. Alexandria, Va: American Statistical Association; 1991:580-585.
15. Rosner B. Fundamentals of Biostatistics. 2nd ed. Boston, Mass: Duxbury Press; 1986:79.
16. Kyprianou N, Martikainen P, Isaacs JT. Programmed cell death of normal and malignant prostatic cells. In: Voigt KD, Knabbe C, eds. Endocrine Dependent Tumors. New York, NY: Raven Press; 1991:69-81.
17. Berry SJ, Coffey DS, Walsh PC. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
18. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy-treated patients. J Urol. 1989; 141:1076-1083.
19. Meyer JS, Sufrin G, Martin SA. Proliferative activity of benign human prostate, prostatic adenocarcinoma, and seminal vesicle evaluated by thymidine labeling. J Urol. 1982;128:1353-1356.